Abeona reports Q2 net income of $7.4M; FDA aligned on pz-cel BLA resubmission for 2H 2024

ABEONA THERAPEUTICS INC.

2024-Q2 EPS reported -$0.72

Net income of $7.4M in Q2 2024 (includes $24.9M gain on warrant liabilities) vs net loss of $16.7M in Q2 2023.
Cash, cash equivalents, short-term investments and restricted cash total $123.0M as of June 30, 2024.
Completed Type A meeting with FDA; preliminary alignment on CMC items; BLA resubmission for pz-cel on track for 2H 2024.
Upon BLA acceptance, FDA expected to set PDUFA action date six months from submission date.
Closed $75M underwritten securities offering in May 2024; $50M credit facility available; cash runway into 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.